ASAQ... Accessible Available in malaria-endemic countries
ASAQ will start being available in 2007, as local marketing authorisations are being granted. Over 25 applications have been filed, in many sub-Saharan countries.
First priority are the 20 countries that have already adopted ASAQ as first-line treatment. Second priority will be countries where ASAQ can be of benefit, based on national and international efficacy data.
Outside of Africa, ASAQ could be beneficial in some other countries in Asia or Latin America, depending on resistance patterns.
Source: RBM-OMSAfro, 2006
Affordable right from the start
For a full treatment cost of <US$0.50 for children less than 5 years old and <US$1 for older children and adults, ASAQ will be available at a “no profit-no loss” price to public organisations of endemic countries, international institutions, NGOs, and programs promoting access to drugs in pharmacies. Further price reduction may be possible, depending on the costs of active ingredients and on amounts ordered by international organisations and the countries concerned.
Different price levels will apply to different drug distribution channels that cater to the needs of different population segments.
- Public market: Artesunate Amodiaquine Winthrop® (AS/AQ Winthrop) sold at “no profit-no loss” price.
- Private market: Coarsucam® for private markets (normal price adapted to local markets) and Coarsucam® Impact Malaria (“no profit-no loss” price) for “Access Card Programme (CAP)” pharmacies.
Non-patented
No patent protection has been sought because this product is provided for the benefit of underprivileged patients, and both DNDi and sanofi-aventis intend wide distribution to those patients in greatest need.
|
